←Back to Expert Scholars
Translational Medicine / 转化医学KRAS G12C Later-Line Therapy
Adrian Sacher
MD
🏢Princess Margaret Cancer Centre🌐Canada
Clinician-Scientist
38
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Adrian Sacher has led clinical trials combining KRAS G12C inhibitors with immunotherapy for later-line NSCLC at Princess Margaret. His research addresses the immunomodulatory effects of KRAS inhibition and optimal sequencing with checkpoint inhibitors. He has contributed to Canadian precision oncology guidelines.
Share:
🧪Research Fields 研究领域
KRAS G12C
Immunotherapy combinations
NSCLC
Later-line therapy
Translational research
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Adrian Sacher 的研究动态
Follow Adrian Sacher's research updates
留下邮箱，当我们发布与 Adrian Sacher（Princess Margaret Cancer Centre）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment